In short
Privosegtor (also known as OCS-05) is an investigational substance being studied for optic neuropathy. One Phase 3 clinical trial, PIONEER 1, is currently authorised and plans to enroll 212 participants. The trial measures the effect of privosegtor versus placebo on low contrast visual acuity (LCVA) at Month 3.
Privosegtor is an investigational substance being studied for optic neuropathy. It is also known by the development code OCS-05. One clinical trial, PIONEER 1, is currently authorised to evaluate its effects.
Key points
- Privosegtor is an investigational substance also known as OCS-05.
- It is being studied in optic neuropathy, a condition affecting the optic nerve.
- The only trial in the data is a Phase 3 study called PIONEER 1.
- The trial is currently authorised and plans to enroll 212 participants.
- The main measurement is change in low contrast visual acuity (LCVA) at Month 3.
What is privosegtor?
Privosegtor is an investigational substance, meaning it is not yet authorised as a medicine. It is also known by the development code OCS-05. The name privosegtor appears in the trial registry record for the PIONEER 1 study.
How does privosegtor work?
The registry record for PIONEER 1 does not describe the mechanism of action of privosegtor. No information is provided in the data about how the substance works at a molecular level.
Which conditions is it studied for?
- Optic neuropathy — a condition affecting the optic nerve, which carries visual information from the eye to the brain. The PIONEER 1 trial studies privosegtor in participants with optic neuropathy.
How is privosegtor given?
The registry record does not state the pharmaceutical form or route of administration for privosegtor. The trial compares privosegtor with placebo, but the data does not specify how either is given.
What do the clinical trials show?
One clinical trial of privosegtor is recorded. PIONEER 1 is a Phase 3 interventional study with a planned enrollment of 212 participants. It is currently authorised, meaning it has received approval to proceed but has not yet reported results.
The trial measures the change in low contrast visual acuity (LCVA) on the 2.5% ETDRS LCVA chart from baseline to Month 3. Low contrast visual acuity is a measure of how well a person can see objects that do not stand out strongly from their background. The study compares privosegtor with placebo.
No results are available yet, as the trial is still in the authorised stage and has not reported outcomes.
What side effects are known?
No information on side effects is available in the provided data. The registry record for PIONEER 1 does not list any adverse events or safety outcomes.